Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | POLM | Q9NP87 | 2/20 | 0.52 |
| ▸ | POLK | Q9UBT6 | 2/20 | 0.52 |
| ▸ | POLL | Q9UGP5 | 2/20 | 0.52 |
| ▸ | POLH | Q9Y253 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29726411 | 1.00 | KMT2A (0.54) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL8707852 | 1.00 | KMT2A (0.54) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL38245 | 1.00 | KMT2A (0.54) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL10815664 | 1.00 | KMT2A (0.54) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL29507312 | 1.00 | KMT2A (0.54) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL38840 | 1.00 | KMT2A (0.54) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL29393577 | 1.00 | KMT2A (0.54) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL38418 | 1.00 | KMT2A (0.54) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL5706066 | 1.00 | KMT2A (0.54) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL25242 | 1.00 | KMT2A (0.54) | KMT2AKDM4EMEN1RECQLPOLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281353-A1 | Use of Metal Hydrazide Complex Compounds as Oxidation Catalysts | BASF SE (DE) | 2013-10-24 | — | — | US | disclosed |
| US-7510859-B2 | Subtilisin variants with improved perhydrolase activity | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20050281773-A1 | Subtilisin variants with improved perhydrolase activity | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2005-12-22 | — | — | US | disclosed |
| CN-1443236-A | Novel amylolytic enzyme extracted from bacillus SP.A7-7(DSM 12368)and washing and cleaning agents containing this novel amylolytic enzyme | HENKEL KGAA (DE) | 2003-09-17 | — | — | CN | disclosed |
| US-4695412-A | Preparation of acyloxybenzenesulfonic acids and their alkali metal and alkaline earth metal salts | BASF AKTIENGESELLSCHAFT (DE) | 1987-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050281773-A1 | Subtilisin variants with improved perhydrolase activity | DPEP1, HPN, DAO | KMT2A 3588/4885KDM4E 1135/4885MEN1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.